INTELLIGENT BIO SOLUTIONS INC.

Intelligent Bio Solutions Inc. announced the completion of precision testing for its Intelligent Fingerprinting Drug Screening System, a crucial step for its FDA 510(k) submission for U.S. market clearance for codeine detection. The testing involved over 1,600 tests across multiple sites and production runs, confirming consistent and reliable results. This data will strengthen the FDA application, bringing the company closer to entering the multi-billion-dollar U.S. drug screening market with its non-invasive technology.

Intelligent Bio Solutions Inc. announced the initiation of an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for codeine detection. The study, involving 75 healthy adults, aims to validate the system's specificity and reliability against potentially interfering substances. Expected to conclude by mid-July 2026, the results will be a crucial part of the comprehensive clinical package for FDA clearance.

Intelligent Bio Solutions Inc. announced the initiation of an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for codeine detection. The study, conducted with CenExel Clinical Research, will assess the system's accuracy and reliability in the presence of potentially interfering substances, enrolling 75 healthy adult participants. This critical FDA-required study is expected to be completed by mid-July 2026, with results included in the FDA submission package alongside data from concurrent Method Comparison and prior Cut-off Studies.

Intelligent Bio Solutions Inc. announced that its management team will participate in the Planet MicroCap Conference from June 16-18, 2026, in Las Vegas, NV. The company's presentation is scheduled for June 17, 2026, at 8:00 – 8:30 AM PDT. Intelligent Bio Solutions will also be available for one-on-one investor meetings throughout the event at Booth 413.

Intelligent Bio Solutions Inc. announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for codeine. The study, conducted in partnership with CenExel Clinical Research, Inc., will evaluate the system's accuracy and real-world performance by typical end-users. The company expects to complete enrollment and data collection by the end of July 2026, with results to be included in its FDA submission.

Intelligent Bio Solutions reported strong financial results for the fiscal third quarter ended March 31, 2026, with revenue growing 46% year-over-year to $1.06 million. Cartridge sales, a key component of its razor-razorblade model, surged 59% year-over-year and accounted for 66% of quarterly sales. The company also achieved a significant operational milestone with its gross profit margin exceeding 50% for the quarter and improving by 800 basis points for the nine-month period, driven by operational efficiencies and increased sales volumes. Strategic progress included advancing its FDA 510(k) regulatory program for U.S. market entry, establishing a new manufacturing partnership, and securing an eighth European patent.

Intelligent Bio Solutions Inc. reported a net loss of $(2,869,640) for the three months ended March 31, 2026, an increase from $(2,550,674) in the prior year, despite revenue growing to $1,060,802. The company also disclosed substantial doubt about its ability to continue as a going concern, citing insufficient cash to fund operations for the next 12 months. As of March 31, 2026, cash and cash equivalents stood at $6,862,204, significantly bolstered by $14.67 million in financing activities during the nine-month period.